The role of glucagon and GLP-1 in the regulation of appetite. Katherine Simpson, Jennifer Parker, Niamh Martin, Ben Field, James Minnion, Mohammad Ghatei.

Slides:

Advertisements

Similar presentations

Advances in Pharmacotherapy with a Focus on Combination Therapy Louis J. Aronne, MD, FACP Clinical Professor of Medicine Weill Cornell Medical College.

Advertisements

GLP-1/Glucagon dual agonist

Regulation of food intake. Food intake Regulation –Endocrine Adipose tissue Pancreas Liver Muscle –CNS.

OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.

Erratic eating in shiftworking health professionals – a potential health risk? AL Jaquiery 1,2,3, T Postelnik 1, V Alderson-Wallace 1, C Wall 1 1 University.

MPB 333 The Molecular Endocrinology of Obesity and Diabetes Satiety and Hunger.

Gut Hormone and The Regulation of Energy Homeostasis Chun-Lung Chiu Chin-Ting Hsu.

Khalilzadeh_s. Obesity is a chronic disease that is causally related to serious medical illnesses Body mass index (BMI) is calculated by dividing a person's.

Endocrine Block | 1 Lecture | Dr. Usman Ghani

Food Regulation Rob Contreras, Ph.D. 018 Longmire

METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.

Docs Adopt© Childhood Obesity Prevention

الجامعة السورية الخاصة كلية الطب البشري قسم طب المجتمع

By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.

Obesity Dr. Sumbul Fatma. Obesity A disorder of body weight regulatory systems Causes accumulation of excess body fat >20% of normal body weight Obesity.

The Endocannabinoid System Role in energy homeostasis and peripheral lipid and glucose metabolism.

CONTROL OF APETITE & METABOLISM. Glucose Homeostasis NORMAL SERUM GLUCOSE mg/dl SERUM GLUCOSE SERUM GLUCOSE ISLET  -CELLS LIVER & MUSCLE METABOLIC.

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Fat Overweight HDL Diabetes Hypertension Depression Caloric value BMI Overeating Insulin Resistance.

Chapter 11 Special Topics in Adult Nutrition: Physical Activity & Weight Management Stella Lucia Volpe PhD,RD,LDN,FACSM.

Obesity is a growing epidemic A disease of enormous proportions >65% adults are overweight >30% adults are obese in US (Ogden et al, 2006) Associated with.

Energy Requirements Living tissue is maintained by constant expenditure of energy (ATP). ATP is Indirectly generated from –glucose, fatty acids, ketones,

Diabetes Update Part 2 of 3 Division of Endocrinology

Insulin Use in Diabetes Mellitus Jennifer Beggs. Introduction History of insulin Manufacture and secretion The insulin receptor Homeostatic role Insulin.

Impact of novel lipidized analogs of neuropeptides on food intake decrease and metabolic changes in rodents Institute of Organic Chemistry and Biochemistry.

MISS 2011 Physiology of Weight Regulation: Implications for Bariatric Surgery Lee M. Kaplan, MD, PhD Gastrointestinal Unit MGH Weight Center

Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA Part 4.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

Effects of Leptin on Exercise and Health in Human.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Effect of a 6-day icv ghrelin infusion (2.5 nmol/d) on cumulative food intake (A), body weight gain (B), food efficiency (C), and fat mass gain (D) Claudia.

Obesity and type 2 diabetes The relationship between obesity and type 2 diabetes can be clearly seen in japanese Sumo wrestlers who are massively obese.

Obesity Dr. Sumbul Fatma. Obesity A disorder of body weight regulatory systems Causes accumulation of excess body fat >20% of normal body weight Obesity.

به نام خدا.

Genes that regulate appetite. Wisse, BE. and Schwartz, MW. The skinny on neurotrophins. Commentary on: Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones.

Relationship of Dopamine Type 2 Receptor Binding Potential With Fasting Neuroendocrine Hormones and Insulin Sensitivity in Human Obesity Featured Article:

Text (Term 2) Ch 12- Hunger Ch 15- Addiction & Reward Ch 10,11- Plasticity, Learning, Memory Ch 17- Emotion, Stress Ch 18- Psychiatric Disorders.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Brain-Gut Interactions in Diabetes Shanthi Srinivasan, M.D. Associate Professor of Medicine.

Metabolic GI peptide hormones Ghrelin Insulin Glucagon Insulin Glucagon GIP GLP-1 Insulin Leptin Insulin Adiposity tissue insulin Insulin.

In the name of God.

TURNING PEPTIDES INTO DRUGS Background Materials & Methods 1) Bataille et al., FEBS Letters, 146, 79-86, ) Gros et al., Endocrinology, 133, ,

A Surgical Rat Model For Investigating Pharmacokinetic Parameters Of Drug Compounds Ioannis Christakis 1, James Minnion 1, Tricia Tan 1, Fausto Palazzo.

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer.

Leptin: Food intake, Energy balance, and Endocrine Function By: Dina M, Trabzuni Advisor; Prof. Hamza Abu-Tarboush 698 FSN.

A New Hope in Management of Hypothalamic Obesity

The New Dual Glucagon-GLP-1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and Type 2 Diabetes Jens R. Daugaard,

Table 1. Pharmacokinetic Parameters of ZP2929 (from ref 1 & 2)

Cravings? Fix your leptin!

Hormones Impacting Food Seeking Behavior

Volume 138, Issue 7, Pages e1 (June 2010)

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Investigating the dose-response relationship of PYY on appetite and visceral illness in rodents. Eleanor Spreckley, BSc, Amin Alamshah, MSc, Katherine.

Exercise and adult women’s health

What do I remember? What is the effect of chronically elevated blood glucose levels on blood vessels? What cardiovascular diseases are a consequence of.

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

High Glycemic Index Metabolic Damage – a Pivotal Role of GIP and GLP-1

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Breakfast Consumption Affects Appetite, Energy Intake, and the Metabolic and Endocrine Responses to Foods Consumed Later in the Day in Male Habitual Breakfast.

Results of sensitivity analyses.

Section overview: Cardiometabolic risk reduction

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 6.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Rapid improvement of glucose tolerance induced by PP

Effects of chow-diet feeding on control and TRIB3 MOE mice.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

The role of glucagon and GLP-1 in the regulation of appetite. Katherine Simpson, Jennifer Parker, Niamh Martin, Ben Field, James Minnion, Mohammad Ghatei and Steve Bloom Dept. Investigative Medicine Academic Trainees Annual Event 5 th May 2011

Obesity and type 2 diabetes mellitus 25% of adults in England are obese (BMI>30 kg/m 2 ) (Health and Social Care Information Centre, 2010)

Type 2 diabetes Insulin resistance and high circulating glucagon GLP-1 analogues: exenatide, liraglutide GLP-1 and glucagon co-agonism: reduced body weight improved glucose profile marginal reduction in food intake increased energy expenditure (Pocai A et al Oct 2009 and Day JW et al Oct 2009)

Gut-brain axis

Pre-proglucagon processing

Peripherally administered: decreases food intake in animals Peripheral effects prevented by: Vagotomy or lesions in the AP and NTS Human studies: Peripheral administration decreases meal size c-fos peripheral GLP-1: AP, NTS, amygdalaand PVN Glucagon and GLP-1

Aims: to answer the following questions (1)What is the effect of co-administration of glucagon and GLP-1 on food intake? (2) Which CNS areas are responsible for this effect?

Effects of glucagon on food intake

Effects of GLP-1 on food intake

‘Subthreshold doses’ of glucagon and GLP-1

Co-administration of glucagon and GLP-1 Saline GLP-1 Glucagon combined

Question 2: Which CNS areas are responsible for these effects on food intake?

AP NTS vagal afferents Brainstem Hypothalamus

Glucagon 750 nmol/kg s/c GLP nmol/kg s/c Saline s/c 250 uM

Dose response c-fos activation in the brainstem following glucagon administration

Dose response c-fos activation in the brainstem following GLP-1 administration

c-fos activation in the brainstem following co-administration of glucagon and GLP-1

No significant differences in hypothalamus Central nucleus of amygdala and reward

Summary Co-administration of glucagon and GLP-1: – decreases food intake to a greater degree than either peptide alone – Increases c-fos expression in similar brainstem areas: AP and NTS

Future work (1)Food intake and CNS pathways: - which neuronal population (2)Chronic effects of dual receptor agonism: - chronic feeding studies in rodents (3) Effects in humans: - glucagon/GLP-1 co-infusion and the effect on food intake

(4) Glucose homeostasis: - glucose tolerance tests (5) Energy expenditure: - calorimetry - BAT mass and UCP-1 mRNA

Acknowledgements Professor Steve Bloom Dr Niamh Martin Jenny Parker, Klara Hostomska, Jamie Plumer Dr James Minnion, Dr Ben Field and Dr Tricia Tan Professor Mohammad Ghatei Wellcome Trust